Exelixis Announces U.S. FDA Accepts for Priority Review the Supplemental New Drug Application for CABOMETYX® (cabozantinib) for Patients with Previously Treated Radioactive Iodine-Refractory Differen
Go back to Exelixis Announces U.S. FDA Accepts for Priority Review the Supplemental New Drug Application for CABOMETYX® (cabozantinib) for Patients with Previously Treated Radioactive Iodine-Refractory Differen| Exelixis, Inc. (NASDAQ: EXEL) | Delayed: 51.34 -0.01 (0.02%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $51.35 | 52 Week High | $17.00 | |||
| Open | $51.39 | 52 Week Low | $3.55 | |||
| Day High | $52.07 | P/E | N/A | |||
| Day Low | $50.88 | EPS | $-1.33 | |||
| Volume | 2,574,378 | |||||
